Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

Published:2015-02-19 Issue:8 Volume:125 Page:1333-1338
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Holtan Shernan G.¹,DeFor Todd E.²,Lazaryan Aleksandr¹,Bejanyan Nelli¹,Arora Mukta¹,Brunstein Claudio G.¹,Blazar Bruce R.¹,MacMillan Margaret L.¹,Weisdorf Daniel J.¹

Affiliation:

1. Blood and Marrow Transplant Program, and

2. Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Abstract

Key Points GRFS is a new composite end point useful for comparing HCT techniques and represents ideal post-HCT recovery. In our cohort of 907 allogeneic HCT recipients, 1-year GRFS was 31%, with best outcomes in recipients of marrow from matched sibling donors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/8/1333/1387499/1333.pdf

Reference21 articles.

1. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.;Sehn;J Clin Oncol,1999

2. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.;Soiffer;Blood,2011

3. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.;Alyea;Biol Blood Marrow Transplant,2002

4. Use of composite endpoints in clinical trials.;Sankoh;Stat Med,2014

5. Bolanos-Meade J Koreth J Reshef R A multi-center phase II trial randomizing novel approaches for graft-versus-host disease prevention compared to contemporary controls (1203). Available at: https://clinicaltrials.gov/ct2/show/NCT02208037. Accessed January 19, 2015

Cited by 401 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients;Toxicology and Applied Pharmacology;2024-10

2. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation;Nature Biotechnology;2024-08-21

3. Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia;Frontiers in Immunology;2024-08-16

4. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period;Cytotherapy;2024-08

5. Effects of Total Body Irradiation on Hematopoietic Cell Transplantation Outcomes in Pediatric Acute Myeloid Leukemia with Prior Central Nervous System Involvement;Transplantation and Cellular Therapy;2024-08